

Cultivating Compassion



DURDANS
HOSPITAL

FINANCIAL STATEMENTS
CEYLON HOSPITALS PLC

FOR THE 1ST QUARTER ENDED 30TH JUNE 2024

CEYLON HOSPITALS PLC

Financial Statements for the quarter ended 30th June 2024

Consolidated Statement of Profit or Loss and Other Comprehensive Income


	Group		Company	
	03 Months Ended 30/06/2024 Unaudited Rs. '000	03 Months Ended 30/06/2023 Unaudited Rs. '000	03 Months Ended 30/06/2024 Unaudited Rs. '000	03 Months Ended 30/06/2023 Unaudited Rs. '000
Revenue	2,236,620	2,200,395	1,340,525	1,225,829
Cost of Sales	(958,996)	(1,003,567)	(581,304)	(566,205)
Gross Profit	1,277,624	1,196,828	759,221	659,624
Other Operating Income	42,448	31,607	16,554	13,073
Administrative Expenses	(875,136)	(800,472)	(555,661)	(506,783)
Other Operating Expenses	(298,579)	(305,102)	(161,918)	(155,731)
Results from Operating Activities	146,357	122,861	58,196	10,183
Finance Cost	(81,449)	(44,176)	(89,381)	(35,010)
Finance Income	28,970	39,001	144,844	166,291
Profit before Taxation	93,878	117,686	113,659	141,464
Taxation	(59,295)	(85,025)	(4,420)	(28,758)
Net Profit after Taxation	34,583	32,661	109,239	112,706
Other Comprehensive Income				
Items will not be reclassified to profit or loss				
Net Change in Fair Value on Equity Investments at FVTOCI	2,451	(1,738)	953	(1,755)
Other Comprehensive Income for the period	2,451	(1,738)	953	(1,755)
Total Comprehensive Income for the quarter	37,034	30,923	110,192	110,951
Profit Attributable to:				
Equity Holders of the Parent	21,636	19,424	109,239	112,706
Non-Controlling Interest	12,947	13,237	-	-
	34,583	32,661	109,239	112,706
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent	23,805	17,683	110,192	110,951
Non-Controlling Interest	13,229	13,240	-	-
	37,034	30,923	110,192	110,951
Earnings per Share - Basic	0.62	0.54	3.15	3.13

The above figures are provisional and subject to audit.


Consolidated Statement of Financial Position


GROUP COMPANY		GROUP COMPANY			
Audited	Audited	Unaudited	Unaudited	Unaudited	Unaudited
As at	As at	As at	As at	As at	As at
31/03/2024	31/03/2024	30/06/2024	30/06/2023	30/06/2024	30/06/2023
Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
ASSETS					
Non-Current Assets					
11,582,383	8,241,211	11,497,349	7,857,718	8,212,539	4,728,291
72,479	66,091	55,696	2,921,006	50,003	2,894,877
1,365	-	1,600	-	-	-
363,571	363,571	373,411	231,960	373,411	231,960
-	1,493,625	-	-	1,493,625	1,457,821
289,393	72,066	295,527	288,972	73,289	76,780
12,309,191	10,236,564	12,223,583	11,299,656	10,202,867	9,389,729
Current Assets					
814,311	642,259	817,168	954,985	592,459	754,058
312,866	199,904	317,077	388,640	201,153	199,550
291,390	164,155	293,985	658,561	157,836	306,921
5,385	66,372	5,289	4,765	76,840	191,043
899,205	45,529	701,035	730,998	118,841	42,924
44,254	37,260	39,025	13,687	35,843	13,342
366,451	212,125	564,061	391,716	427,462	283,343
2,733,862	1,367,604	2,737,640	3,143,352	1,610,434	1,791,181
15,043,053	11,604,168	14,961,223	14,443,008	11,813,301	11,180,910
Total Assets					
EQUITY AND LIABILITIES					
Equity Attributable to Equity holders of the parent					
1,142,798	1,142,798	1,692,704	1,142,798	1,692,704	1,142,798
2,290,344	1,742,664	2,290,344	2,290,344	1,742,664	1,742,664
74,340	(659)	76,509	75,102	294	4,557
4,595,643	2,963,955	4,543,493	4,198,439	2,999,409	2,842,162
8,103,125	5,848,758	8,603,050	7,706,683	6,435,071	5,732,181
733,044	-	716,984	708,939	-	-
8,836,169	5,848,758	9,320,034	8,415,622	6,435,071	5,732,181
Non-Current Liabilities					
1,989,051	1,872,910	1,482,610	2,201,991	1,377,201	2,025,121
279,087	279,087	275,514	171,629	275,514	171,629
-	28,580	-	-	28,107	34,368
227,265	203,793	234,196	208,539	210,744	186,199
1,389,826	1,063,004	1,397,773	1,310,997	1,066,004	1,010,120
467,500	-	-	-	467,500	510,000
3,885,229	3,914,874	3,390,093	3,893,156	3,425,070	3,937,437
Current Liabilities					
542,805	413,050	619,767	552,409	536,225	468,861
488,626	428,928	501,855	403,733	428,929	374,044
120,416	120,416	120,416	99,649	120,416	99,649
1,027,015	551,023	972,937	993,265	483,104	518,342
-	-	22,316	68,865	-	25,366
142,793	327,119	13,807	16,309	384,487	25,030
2,321,655	1,840,536	2,251,098	2,134,230	1,953,161	1,511,292
15,043,053	11,604,168	14,961,223	14,443,008	11,813,301	11,180,910
Total Equity and Liabilities					

The above figures are provisional and subject to audit.


Thusitha Rubasinghe
Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.
Signed for and on behalf of the Board by,


A E Tudawe
Chairman


U D Tudawe
Director

13th August 2024

Group

	Attributable to equity holders of the parent					Non-Controlling Interests Rs. '000	Total Equity Rs. '000
	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000		
Balance as at 31st March 2023 - Audited	1,142,798	2,290,344	76,843	4,261,864	7,771,850	729,501	8,501,350
Net Profit for the year ended 31 March 2024	-	-	-	417,194	417,194	36,618	453,812
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,503)	-	(2,503)	1,037	(1,466)
Actuarial Gain on Gratuity Valuation	-	-	-	673	673	(265)	408
Deferred Tax effect on Gratuity Valuation	-	-	-	(755)	(755)	(45)	(800)
Total Comprehensive Income for the year ended 31 March 2024	-	-	(2,503)	417,112	414,609	37,345	451,954
Transactions with Owners in their capacity as Owners							
Rights Issue Expenses	-	-	-	(557)	(557)	-	(557)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)	(33,802)	(116,578)
	-	-	-	(83,333)	(83,333)	(33,802)	(117,135)
Balance as at 31st March 2024 - Audited	1,142,798	2,290,344	74,340	4,595,643	8,103,125	733,044	8,836,169
Net Profit for the quarter ended 30 June 2024	-	-	-	21,636	21,636	12,947	34,583
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	2,169	-	2,169	282	2,451
Total Comprehensive Income for the quarter ended 30 June 2024	-	-	2,169	21,636	23,805	13,229	37,034
Transactions with Owners in their capacity as Owners							
Shares issued at Rights Issue	549,906	-	-	-	549,906	-	549,906
Rights Issue Expenses	-	-	-	(1,806)	(1,806)	-	(1,806)
Dividend Paid - Ordinary Shares	-	-	-	(71,980)	(71,980)	(29,289)	(101,269)
Balance as at 30th June 2024	1,692,704	2,290,344	76,509	4,543,493	8,603,050	716,984	9,320,034

Company

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000
Balance as at 31st March 2023 - Audited	1,142,798	1,742,664	6,312	2,812,305	5,704,079
Net Profit for the year ended 31 March 2024	-	-	-	233,631	233,631
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(6,971)	-	(6,971)
Actuarial Gain on Gratuity Valuation	-	-	-	1,931	1,931
Deferred Tax Effect on Gratuity Valuation	-	-	-	(579)	(579)
Total Comprehensive Income for the year ended 31 March 2024	-	-	(6,971)	234,983	228,012
Transactions with Owners in their capacity as Owners					
Rights Issue Expenses	-	-	-	(557)	(557)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)
	-	-	-	(83,333)	(83,333)
Balance as at 31st March 2024 - Audited	1,142,798	1,742,664	(659)	2,963,955	5,848,758
Net Profit for the quarter ended 30 June 2024	-	-	-	109,239	109,239
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	953	-	953
Total Comprehensive Income for the quarter ended 30 June 2024	-	-	953	109,239	110,192
Transactions with Owners in their capacity as Owners					
Shares issued at Rights Issue	549,906	-	-	-	549,906
Rights Issue Expenses	-	-	-	(1,806)	(1,806)
Dividend Paid - Ordinary Shares	-	-	-	(71,980)	(71,980)
Balance as at 30th June 2024	1,692,704	1,742,664	294	2,999,409	6,435,071

Consolidated Statement of Cash Flows

Group Audited 12 Months Ended 31/03/2024 Rs '000	Company Audited 12 Months Ended 31/03/2024 Rs '000		Group Unaudited 03 Months Ended 30/06/2024 Rs '000	Unaudited 03 Months Ended 30/06/2023 Rs '000	Company Unaudited 03 Months Ended 30/06/2024 Rs '000	Unaudited 03 Months Ended 30/06/2023 Rs '000
Cash Flows from/ (Used in) Operating Activities						
658,886	293,937	Net Profit Before Income Tax Expenses	93,878	117,686	113,659	141,464
		Adjustments for :				
26,519	18,537	Inventory Write-off/(Write in)	3,504	10,793	2,896	9,986
49,230	39,240	Bad Debts Write-off	-	450	-	450
442,576	230,162	Depreciation Charge	140,315	112,213	81,598	54,545
124,577	124,577	Amortisation of Right of use assets	35,874	29,175	35,874	29,175
(99,656)	(171,816)	Finance Income	(28,970)	(39,001)	(144,844)	(166,291)
144,669	147,984	Finance Cost	81,449	44,176	89,380	35,010
-	(1,890)	Amortisation of Deferred Rent Expenses/(Income)	-	-	(473)	(473)
(17,755)	(1,550)	(Profit)/ Loss on Disposal of Property, Plant and Equipment	-	-	-	-
-	-	(Profit)/ Loss on Disposal of Financial Instruments	(1,090)	-	(1,090)	-
(102,117)	(2,079)	Fair value (Gain)/Loss on Financial Instruments	(29,625)	(13,103)	(1,570)	(250)
(1,113)	(1,113)	Unclaimed Dividends	-	-	-	-
(160)	-	Creditors written back	-	-	-	-
19,814	-	Unclaimed VAT	-	-	-	-
57,627	50,804	Provision for Defined Benefit Plans	17,469	10,260	16,044	9,000
1,303,097	726,793	Operating Profit before Working Capital Changes	312,804	272,649	191,474	112,616
179,302	146,797	(Increase)/Decrease in Inventories	(6,361)	54,354	46,905	43,550
330,379	130,061	(Increase)/Decrease in Trade and Other Receivables	(6,806)	(44,423)	5,071	26,439
147,995	100,441	Increase/(Decrease) in Trade and Other Payables	(54,079)	114,086	(67,918)	81,648
142,738	252,236	(Increase)/Decrease Related Party Dues	(128,890)	16,873	46,899	(140,220)
2,103,511	1,356,328	Cash Generated from Operations	116,668	413,539	222,431	124,033
(144,669)	(120,885)	Finance Cost Paid	(81,449)	(44,176)	(89,380)	(35,010)
(35,369)	(27,807)	Defined Benefit Plan Costs Paid	(10,538)	(7,135)	(9,093)	(5,528)
(198,041)	(60,608)	Income Tax/WHT Paid	(29,922)	(90,935)	(4)	(32,636)
1,725,432	1,147,028	Net Cash from Operating Activities	(5,241)	271,293	123,954	50,859
Cash Flows from/ (used in) Investing Activities						
(958,307)	(480,682)	Acquisition of Property, Plant and Equipment	(48,041)	(580,472)	(36,838)	(444,870)
(827,135)	(823,939)	Acquisition of Capital work in progress	-	-	-	-
(1,600)	-	Purchase of Intangible Assets	-	-	-	-
6,430	1,550	Proceeds from Sale of Property, Plant and Equipment	-	-	-	-
42,879	-	Proceeds on Sale of Shares/Units	-	-	-	-
(50,184)	(32,175)	(Acquisition)/ Disposal of other Investments	245,461	67,732	(81,088)	2,168
99,657	171,816	Income from Investments	28,970	39,001	144,844	166,291
(1,688,260)	(1,163,430)	Net Cash Flows from/ (used in) Investing Activities	226,390	(473,739)	26,918	(276,411)
Cash Flows from/ (used in) Financing Activities						
375,000	360,000	Receipts from Interest Bearing Loans and Borrowings	-	300,000	-	300,000
(254,128)	(194,712)	Re-payments to Interest Bearing Loans and Borrowing	(508,212)	(51,080)	(495,710)	(37,385)
(154,378)	(154,379)	Lease Rent Payment	(39,120)	(27,632)	(39,120)	(27,632)
-	-	Proceeds on Shares issued at Rights Issue	549,906	-	549,906	-
(557)	(557)	Right Issue Expenses	(1,806)	(73)	(1,806)	(73)
(116,579)	(82,776)	Dividends Paid	(101,269)	(116,578)	(71,980)	(82,776)
(150,642)	(72,424)	Net Cash Flows from/ (used in) Financing Activities	(100,501)	104,637	(58,710)	152,134
(113,470)	(88,825)	Net Increase/ (Decrease) in Cash and Cash Equivalents	120,648	(97,809)	92,162	(73,418)
(62,884)	(112,100)	Cash and Cash Equivalents at the Beginning of the Year	(176,354)	(62,884)	(200,925)	(112,100)
(176,354)	(200,925)	Cash and Cash Equivalents at the End of the Period	(55,706)	(160,693)	(108,763)	(185,518)
Analysis of Cash and Cash Equivalents						
(542,805)	(413,050)	Bank Overdraft	(619,767)	(552,409)	(536,225)	(468,861)
366,451	212,125	Cash in Hand and at Bank	564,061	391,716	427,462	283,343
(176,354)	(200,925)		(55,706)	(160,693)	(108,763)	(185,518)

Explanatory Notes

01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the quarter ended 30 June 2024, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the quarter ended 30 June 2024 were authorised for issue by the Board of Directors on 13th August 2024.

04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

4.1 Basis of preparation

The interim financial statements for the quarter ended 30 June 2024 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 March 2024.

4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the nine months were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Investments in quoted shares, Investments in Debentures and Refundable deposits are classified under non current financials assets while Investments in Unit Trusts, Investment in quoted shares (Trading) and Investments in Fixed Deposits are classified under current financial assets.

Recurring Fair Value Measurement As at 30th June 2024	Group				Company			
	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.
<u>Fair Value through Other Comprehensive Income</u>								
Equity Shares in Listed Companies	24,511,836	-	-	24,511,836	1,630,565	-	-	1,630,565
	24,511,836	-	-	24,511,836	1,630,565	-	-	1,630,565
<u>Fair Value through Profit or Loss</u>								
Equity Shares in Listed Companies	267,656,961	-	-	267,656,961	-	-	-	-
Investments in Unit Trusts	321,919,747	-	-	321,919,747	118,841,019	-	-	118,841,019
	589,576,708	-	-	589,576,708	118,841,019	-	-	118,841,019

05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements other than what is disclosed in the Annual Report 2023/2024.

06. Events occurring after the Balance Sheet date

There were no material events occurring after the balance sheet date that require adjustments or disclosure in the Financial Statements.

07. The EGM for the proposed Rights Issue was held on 14th May 2024, to raise Rs.550 Mn to settle high priced borrowings as announced to the Colombo Stock Exchange

The Rights Issue to raise Rs. 550Mn took place during the quarter and proceeds was utilized to settle high priced borrowings.

08. Related party transactions for the quarter ended 30 June 2024 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

Related Party Transactions
For the quarter ended 30 June 2024

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs'000
Durdans Management Services Ltd	Ultimate Parent	Management fee Providing utilities and other cost	Recurrent Recurrent	10,890 4
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend Received Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	9,100 8,894 120,316 134,043 15,157 35,528 67
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend Received Purchases of Drugs and consumables Receiving of medical services	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	1,597 4,873 33,284 10,322 1,452 396
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rent Received Providing utilities and other cost	Recurrent Recurrent	5,841 1,906
Ceygen Biotech (Pvt) Ltd	Subsidiary	Rent Received	Recurrent	385
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Sale of Drugs and consumables Purchases of Drugs and consumables	Recurrent Recurrent	39 54,846

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs'000
Tudawe Brothers (Pvt) Ltd	Affiliate	Vision 2022 Construction Cost	Non Recurrent	5,978
Tudawe Engineering Services (Pvt) Ltd	Affiliate	Vision 2022 Construction Cost	Non Recurrent	3,898

Share Information

Number of Shares Represented in Stated Capital

Voting Shares	30,997,401
Non-Voting Shares	10,133,765
Total	<u>41,131,166</u>

The voting shares of 3,874,675 and the non voting shares of 1,266,721 issued through Rights issue in June 2024 that was listed on Colombo Stock Exchange on 03rd July 2024 has been included in the share information above.

Public Shareholding as at 03rd July 2024

	Voting	Non-Voting
Number of shareholders	2,386	1,338
Number of shares	6,400,096	5,095,055
Holding Percentage	20.65%	50.28%
Float Adjusted Market Capitalisation (Rs Mn)	719	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

Directors' and Chief Executive Officer's Shareholding as at 03rd July 2024

	Number of Shares	
	Voting	Non-Voting
Mr. A. E. Tudawe	272,590	-
Mr. U. D. Tudawe	209,776	-
Dr A. D. P. A. Wijegoonewardene	268,743	-
Mr. Y. N. R. Piyasena	597,824	-
Mr. A. D. B. Talwatte	1,213	-
Mr. A.V.R. De Silva Jayatilleke	121	-
Mr. A.S. Tudawe	51	1,062
Mr. S. Renganathan	-	-
Mr. H.M.A. Jayasinghe	-	-

Market Prices recorded during the Quarter

	Highest Traded Price		Lowest Traded Price		Last Traded Price	
	2024/25	2023/24	2024/25	2023/24	2024/25	2023/24
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
Voting	130.00 06/05/2024	138.75 03/04/2023	113.00 29/05/2024	110.00 16/06/2023	120.75 28/06/2024	119.75 27/06/2023
Non - Voting	108.25 13/05/2024	119.00 26/06/2023	92.00 05/04/2024	96.00 03/04/2023	94.50 28/06/2024	113.00 28/06/2023

Per Share Ratios

	Group		Company	
	As at	As at	As at	As at
	30/06/2024	30/06/2023	30/06/2024	30/06/2023
	Rs.	Rs.	Rs.	Rs.
Earnings Per Share	0.62	0.54	3.15	3.13
Net Asset Per Share	209.16	214.14	156.45	159.27

Top 20 Shareholders Listed as at 03 July 2024**Voting Shareholders**

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	21,574,963	69.60
Mr. D.G. Wijemanna	do	730,597	2.36
Lawrance Tudawe Management Services (Pvt) Ltd	do	728,663	2.35
Mr. R.P. Weerasooriya	do	701,457	2.26
Mr. Y. N. R. Piyasena	do	597,824	1.93
Mr. Deen Mohamed Fazal Aslam	do	551,142	1.78
Galle Face Capital Partners PLC	do	518,791	1.67
Mr. Merrill J. Fernando (Deceased)	do	390,500	1.26
Cargo Boat Development Company PLC	do	370,945	1.20
MJF Holdings (Pvt) Ltd	do	287,917	0.93
Mr. A. E. Tudawe	do	272,590	0.88
Dr. A. D. P. A. Wijegoonewardene	do	268,743	0.87
Mr. U. D. Tudawe	do	209,776	0.68
Mr. H. L. Tudawe	do	200,494	0.65
Mr. A. D. Tudawe	do	196,694	0.63
Mr. P.V. Tudawe	do	166,789	0.54
Commercial Bank of Ceylon PLC A/C No. 04	do	88,187	0.28
E.W. Balasuriya & Co. (Pvt) Ltd	do	86,006	0.28
Merrill J Fernando & Sons (Pvt) Ltd	do	80,914	0.26
Mr. G. A. Tudawe	do	77,576	0.25
		28,100,568	90.66

Non-Voting Shareholders

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	3,588,133	35.41
Employees' Provident Fund	do	1,154,371	11.39
MJF Holdings (Pvt) Ltd	do	636,061	6.28
E. W. Balasuriya & Co. (Pvt) Ltd	do	401,465	3.96
Mr. D. Ratnayake	do	156,045	1.54
Mr. L.J.M.A. Jayasundara	do	150,500	1.49
Tudawe Engineering Services (Pvt) Ltd	do	111,697	1.10
Mr. D. A. Cabraal	do	100,178	0.99
Mr. A. H. Munasinghe	do	98,141	0.97
Mr. S. S. Sithambaranathan	do	94,357	0.93
Mr. A. D. Tudawe	do	86,396	0.85
Ms. T. T. Weerasinghe	do	80,554	0.79
Mr. D. G. Wijemanna	do	77,728	0.77
Mr. P. S. De Mel	do	75,248	0.74
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	72,857	0.72
Saman Villas Limited	do	70,988	0.70
Commercial Bank of Ceylon PLC A/C No. 04	do	64,918	0.64
Mr. G. D. M. Ranasinghe	do	62,857	0.62
Mr. D.P. L. De Mel	do	62,589	0.62
Mr. A. H. Munasinghe	do	61,269	0.60
		7,206,352	71.11

CEYLON HOSPITALS PLC

CORPORATE INFORMATION

Name of Company

Ceylon Hospitals PLC

Brand Name

DURDANS

Legal Form

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

Company Registration Number

PQ 113

Stocks Exchange Listing

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

Registered Office

No.03, Alfred Place, Colombo 03.

Bankers

Bank of Ceylon
Commercial Bank of Ceylon PLC
DFCC Bank PLC
Hatton National Bank PLC
National Development Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Seylan Bank PLC
Union Bank of Colombo PLC
People's Bank

Auditors

Messers.B.R.De.Silva & Co.
Chartered Accountants
No. 22/4, Vijaya Kumaratunga Mawatha
Colombo 05.

Lawyers

Mr. D.F.R. Jayamaha
Hector Jayamaha Law Office,
No.228,Thimbirigasyaya Road,
Colombo 05.

Secretaries

Nexia Corporate Consultants (Pvt) Ltd
No. 130, Level 02, Nawala Road,
Narahenpita. Colombo 05.

Registrars

S S P Corporate Services (Pvt) Ltd
546, Galle Road,
Colombo 03.



CEYLON HOSPITALS PLC

3 Alfred Place, Colombo 3, Sri Lanka

T +94 (0) 11 2 140 000 F +94 (0) 11 2 575 302 E contactus@durdans.com W durdans.com

Dedicated to you